Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of BCT301 Therapy for Refractory Autoimmune Diseases
NCT07301164Phase 1Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCT301 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), antiphospholipid syndrome (APS) and 3 more, sponsored by Peking University Third Hospital. Primary endpoint: Dose-limiting toxicities at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
BCT301
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)antiphospholipid syndrome (APS)inflammatory myositisSjögren's syndrome
Beyond the preview
Go deeper on NCT07301164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301164.